Previous 10 | Next 10 |
(NewsDirect) Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt joined Thomas Warner from Proactive ahead of World Brain Day to provide an update on the biotechnology company's novel multiple sclerosis (MS) treatment. Dr Vitt gives an overview of the treatment that Immunic is ...
2023-07-03 10:30:53 ET Gainers: Ensysce Biosciences ( ENSC ) +20% . Journey Medical ( DERM ) +20% . Ventyx Biosciences ( VTYX ) +16% . PainReform ( PRFX ) +12% . iCAD ( ICAD ) +7% . Losers: Protagonist Therapeutics ( PTG...
2023-06-30 08:40:05 ET Renalytix ( RNLX ) +38% jumps 38% after FDA nod for lead product. TOP Financial Group ( TOP ) +25% . Bright Health Group ( BHG ) +19% enters into definitive agreement with Molina Healthcare to sell its California Medicare Adva...
Immunic to Participate in Scientific and Investor Conferences in July PR Newswire NEW YORK , June 29, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapie...
2023-06-28 13:55:47 ET Gainers: Centogene ( CNTG ) +45% . Joby Aviation ( JOBY ) +41% . Kaleyra ( KLR ) +39% . GEN Restaurant Group ( GENK ) +27% . Lilium ( LILM ) +26% . IonQ ( IONQ ) +22% . Beneficient ( BENF ...
--News Direct-- Immunic Therapeutics Chief Scientific Officer Hella Kohlhof joins Natalie Stoberman from the Proactive newsroom to share the recently released mode of action, molecular target, preclinical data for its IMU-856 asset that targets restoration of intestinal barrier function a...
--News Direct-- Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com View original content to download multimedia: https://newsdirect.com/news/immunic-ultimately-hoping-to-offer-patients-a-new-kind-of-treatment-for-multiple-sclero...
Immunic to Participate in Scientific and Investor Conferences in June PR Newswire NEW YORK , May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...
2023-05-25 19:36:30 ET Summary It is expected that the market opportunity for disease-modifying therapies for MS will reach $29.8 billion in 2030; further projected that OCREVUS could generate sales of $6.3 billion by 2030. Roche Holding AG reported positive results reported from ...
(NewsDirect) Immunic Inc president and CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of preclinical data confirming that vidofludimus calcium (IMU-838) acts as a potent nuclear receptor-related 1 (Nurr1) activator, in addition to its known mode of acti...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...